Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Novo_Nordisk
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:CEO |
gptkb:Marc_de_Garidel
|
| gptkbp:focusesOn |
cardiovascular diseases
inflammatory diseases |
| gptkbp:foundedIn |
2015
|
| gptkbp:founder |
gptkb:Michael_Davidson
gptkb:Dong_Seop_Kim gptkb:Marc_de_Garidel gptkb:Ram_Aiyar |
| gptkbp:headquartersLocation |
gptkb:Waltham,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Corvidia Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:ziltivekimab
|
| gptkbp:numberOfEmployees |
approximately 50 (at time of acquisition)
|
| gptkbp:website |
https://www.corvidiatx.com/
|
| gptkbp:bfsParent |
gptkb:Sofinnova_Partners
gptkb:Novo_Holdings |
| gptkbp:bfsLayer |
7
|